8-K: Titan Pharma Completes Merger, Becomes Black Titan Subsidiary
Merger Completion Announcement
Titan Pharmaceuticals, Inc. completed its business combination with Black Titan Corporation, resulting in TTNP becoming a wholly-owned subsidiary and its shares converting to Black Titan Ordinary Shares.
Summary
- Titan Pharmaceuticals, Inc. (TTNP) completed its previously announced business combination with Black Titan Corporation (PubCo) on October 1, 2025.
- TTNP Merger Sub, Inc. merged with and into TTNP, with TTNP continuing as the surviving corporation and a direct wholly-owned subsidiary of Black Titan.
- Each share of TTNP Capital Stock issued and outstanding immediately prior to the Effective Time was automatically converted into Ordinary Shares of Black Titan (PubCo Ordinary Shares).
- TalenTec Sdn. Bhd. shareholders also contributed and exchanged all of their TalenTec shares for PubCo Ordinary Shares.
- Shares of TTNP common stock are anticipated to cease trading on the Nasdaq Capital Market.
- PubCo Ordinary Shares are anticipated to begin trading on Nasdaq commencing with the opening of trading on Thursday, October 2, 2025.
Sentiment
Score: 7
Explanation: The filing announces the successful completion of a previously disclosed merger, which is generally a positive sign of execution and provides clarity on the future trading of the combined entity's shares. It represents a planned strategic transition.
Positives
- The successful completion of a previously announced strategic business combination provides clarity and execution on a planned corporate restructuring.
- TTNP shareholders will receive shares in Black Titan, ensuring continued market access for their equity interest on Nasdaq.
Negatives
- Titan Pharmaceuticals, Inc. ceases to exist as an independent publicly traded entity.
- Existing TTNP stockholders immediately prior to the merger ceased to have any rights as stockholders of TTNP, other than the right to receive Black Titan Ordinary Shares.
Future Outlook
Black Titan Ordinary Shares are anticipated to begin trading on the Nasdaq Capital Market commencing with the opening of trading on Thursday, October 2, 2025.
Management Comments
- TTNP's directors and officers offered their resignations for serving in such capacities at the request of Black Titan, and not because of any disagreement with TTNP regarding any matter related to TTNP's operations, policies, or practices.
Industry Context
This transaction represents a consolidation event, common in sectors like pharmaceuticals or related technology, where companies merge for strategic alignment, market expansion, or technology integration. It signifies a structural change for Titan Pharmaceuticals, now operating under the umbrella of Black Titan Corporation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Directors and Officers of TTNP | All existing directors and officers of TTNP | NA | October 1, 2025 | Resigned at the request of Black Titan as part of the merger. |
| Sole Director and Acting Secretary of TTNP | NA | Chay Weei Jye | October 1, 2025 | Appointed by Black Titan as part of the merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Change in Control and Board Composition | Titan Pharmaceuticals, Inc. became a direct wholly-owned subsidiary of Black Titan Corporation. All previous TTNP directors and officers resigned, and Chay Weei Jye was appointed as the sole director and acting secretary of TTNP. | October 1, 2025 | Complete change in the corporate governance structure for TTNP, which is now under the direct control and management of Black Titan. |
Related Party Transactions
- The business combination itself, involving Titan Pharmaceuticals, Black Titan Corporation, TTNP Merger Sub, Inc., and TalenTec Sdn. Bhd., constitutes a significant related party transaction as part of the merger agreement.
Stakeholder Impact
- Shareholders: Existing TTNP shareholders' stock has been converted into Black Titan Ordinary Shares, maintaining their equity interest in the combined entity, which will continue to trade on Nasdaq.
- Management/Employees: Significant changes in TTNP's management occurred with the resignation of all previous directors and officers and the appointment of new leadership, indicating potential broader organizational impacts.
Next Steps
- TTNP common stock will cease trading on the Nasdaq Capital Market.
- Black Titan Ordinary Shares will begin trading on Nasdaq on October 2, 2025.
Key Dates
| Date | Description |
|---|---|
| August 19, 2024 | Date of the Merger and Contribution and Share Exchange Agreement. |
| July 25, 2025 | Date of the Share Exchange Agreement among PubCo, TalenTec, and TalenTec Shareholders. |
| October 1, 2025 | Effective Time of the Merger; Completion of the business combination; Resignations of TTNP directors and officers; Appointment of Chay Weei Jye as sole director and acting secretary of TTNP. |
| October 2, 2025 | Anticipated commencement of trading for Black Titan Ordinary Shares on Nasdaq. |
Recommendation
holdThe filing confirms the successful execution of a previously announced strategic transaction, converting Titan Pharmaceuticals shares into Black Titan Ordinary Shares. For existing TTNP shareholders, this is a change in the security held, and a 'hold' recommendation is appropriate as the immediate impact is the transition to the new entity. Further evaluation of Black Titan's consolidated business and future prospects would be necessary for a more definitive 'buy' or 'sell' stance for new investors.
Keywords
Titan Pharmaceuticals, Black Titan Corporation, TalenTec, Merger, Acquisition, Business Combination, Nasdaq, 8-K, Corporate Governance, Share Exchange, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.